Clinical trials in Varese – page 26

2 655 clinical trials in Varese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Varese at a glance

2 655

clinical trials

Research sites1

Quick filters

2 655 trials in Varese

Open in trial search

Chronic lymphocytic leukaemia

Recruiting

A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

Registered drugNo placebo

A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Emavusertib
Sponsor:Curis Inc.

Contact Research Centre

Duchenne muscular dystrophy

Recruiting

A study to evaluate the long-term safety and effectiveness of BMN 351 in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

InvestigationalNo placebo

A study to evaluate the long-term safety and effectiveness of BMN 351 in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:BMN 351
Sponsor:Biomarin Pharmaceutical Inc.

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Mantle cell lymphoma recurrent+1

Recruiting

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Janssen Cilag International

Contact Research Centre

Angelman's syndrome

Recruiting

A Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome

InvestigationalNo placebo

A Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome

InvestigationalNo placebo

Italy

Participants:0–17 years · 18–64 years
Sponsor:Ionis Pharmaceuticals Inc.

Contact Research Centre

Thrombotic thrombocytopenic purpura+1

Recruiting

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
Sponsor:TargED Biopharmaceuticals B.V.

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Novartis Pharma AG

Contact Research Centre

Cardiac function disturbance postoperative+1

Recruiting

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:R2R01
Sponsor:River 2 Renal Corp.

Contact Research Centre

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:SAR445399
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Varese

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on blood cancers and lymphomas, including studies of novel therapies for acute myeloid leukemia and chronic myeloid leukemia. Clinical trials are evaluating innovative treatment combinations and maintenance strategies.

Follicular Lymphoma Treatment Optimization
Leukemia Targeted Therapies
B-cell Lymphoma Management

Investigations include maintenance therapies and comparison of shortened versus standard chemotherapy protocols combined with immunotherapy.

02 Thoracic Oncology

Comprehensive studies on non-small cell lung cancer and pleural mesothelioma, exploring innovative combination therapies and targeted treatments for specific genetic mutations.

EGFR-TKI Sequencing Studies
Immunotherapy Combinations
Targeted Molecular Therapies

Research focuses on personalized treatment approaches and novel drug combinations to improve patient outcomes.

03 Cardiovascular Medicine

Advanced research in cardiovascular disease and thrombosis, with trials examining innovative treatments for reducing cardiovascular events and managing blood clots.

Lipoprotein Management
Deep Vein Thrombosis Treatment
Cardiovascular Risk Reduction

Studies aim to evaluate new therapeutic approaches for preventing major cardiovascular events and improving patient outcomes.

Back to Italy All countries